BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33547202)

  • 1. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
    Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
    Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma.
    Hiroshima Y; Kasajima R; Kimura Y; Komura D; Ishikawa S; Ichikawa Y; Bouvet M; Yamamoto N; Oshima T; Morinaga S; Singh SR; Hoffman RM; Endo I; Miyagi Y
    Cancer Lett; 2020 Jan; 469():217-227. PubMed ID: 31669204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma.
    Robin F; Angenard G; Cano L; Courtin-Tanguy L; Gaignard E; Khene ZE; Bergeat D; Clément B; Boudjema K; Coulouarn C; Sulpice L
    Br J Cancer; 2020 Jul; 123(1):72-80. PubMed ID: 32376891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma.
    Kalloger SE; Karasinska JM; Keung MS; Thompson DL; Ho J; Chow C; Gao D; Topham JT; Warren C; Wong HL; Lee MK; Renouf DJ; Schaeffer DF
    Int J Cancer; 2021 Jan; 148(2):481-491. PubMed ID: 32955725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
    Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
    Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
    Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related genes
    Zhang M; Zeng L; Peng Y; Fan B; Chen P; Liu J
    Future Oncol; 2021 Aug; 17(23):3061-3076. PubMed ID: 34156282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
    Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
    Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
    [No Abstract]   [Full Text] [Related]  

  • 14. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
    Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
    Shang M; Zhang L; Chen X; Zheng S
    Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
    Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.